Next Steps: What to Do When the First Non-Hodgkin Lymphoma Treatment You Try Doesn’t Work

Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated December 27th, 2022

Next Steps: What to Do When the First Non-Hodgkin Lymphoma Treatment You Try Doesn’t Work

NOW
PLAYING
Zanubrutinib May Delay Disease Progression in Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma
NOW
PLAYING
Is A Restrictive Neutropenic Diet Really Necessary After a Bone Marrow Transplant?
NOW
PLAYING
Real-World Implications Of Her2 Low- The Major New Breast Cancer Designation And Its Treatment-- How Low Is Too Low?
NOW
PLAYING
New Data: The Drug Ibrutinib May Help Some Younger Mantle Cell Lymphoma Patients Avoid A Stem Cell Transplant
NOW
PLAYING
Changing Landscape Of Ovarian Cancer Treatment: PARP Inhibitor Drugs Withdrawn For Some Indications
NOW
PLAYING
Newly FDA-Approved Drug Elahere May Be Effective Treatment For Patients With A Particularly Aggressive Form Of Ovarian Cancer

Patient Pathfinder:

Clinical Trial Finder

Are you looking for other treatment options?
Right now there are ... non-hodgkin lymphoma trials in the U.S. within 100 miles of

Enter your zip code and travel distance to explore trials in your area...

Recurrence: Options After Diffuse Large B-Cell Lymphoma Recurrence

SEE MORE   

  • There are several treatment options available if non-Hodgkin lymphoma returns
  • The most common first treatment after relapse is another round of chemotherapy
  • For patients whose cancer does not respond well to chemo, doctors may explore immune-therapies such as CAR-T therapy

Recurrence: Options After Diffuse Large B-Cell Lymphoma Recurrence

  • There are several treatment options available if non-Hodgkin lymphoma returns
  • The most common first treatment after relapse is another round of chemotherapy
  • For patients whose cancer does not respond well to chemo, doctors may explore immune-therapies such as CAR-T therapy
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.